DBV Technologies (NASDAQ:DBVT) Now Covered by StockNews.com

Equities researchers at StockNews.com began coverage on shares of DBV Technologies (NASDAQ:DBVT) in a report released on Sunday. The firm set a “hold” rating on the stock.

A number of other analysts also recently commented on the company. HC Wainwright upped their price objective on DBV Technologies from $25.00 to $35.00 and gave the stock a “buy” rating in a report on Thursday, October 24th. JMP Securities reaffirmed a “market outperform” rating and issued a $10.00 target price on shares of DBV Technologies in a research report on Friday, January 10th.

DBV Technologies Price Performance

DBV Technologies stock opened at $4.13 on Friday. The stock’s fifty day moving average is $3.75 and its two-hundred day moving average is $3.87. The stock has a market cap of $84.85 million, a PE ratio of -0.92 and a beta of 0.67. DBV Technologies has a 1-year low of $2.20 and a 1-year high of $9.40.

DBV Technologies (NASDAQ:DBVT) last issued its earnings results on Wednesday, November 6th. The company reported ($0.80) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.90) by $1.10. DBV Technologies had a negative return on equity of 106.07% and a negative net margin of 815.73%. The business had revenue of $1.07 million during the quarter, compared to the consensus estimate of $1.17 million. On average, research analysts expect that DBV Technologies will post -7.05 earnings per share for the current fiscal year.

DBV Technologies Company Profile

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis.